He et al. designed, synthesized, and evaluated hydroxamic acid-based compounds as a dual inhibitor of N-methyl-D-aspartase receptor (NMDAR) and HDAC for Alzheimer’s disease. Here, HDAC9 is linked to early-onset autosomal dominant Alzheimer disease.